Exelixis Inc (EXEL)

Add to Watchlists
Create an Alert
Quickflows
23.94 -0.43  -1.76% NASDAQ Jul 16, 09:50 Delayed 2m USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All EXEL News

News

View All Events

Events

Date Type Description
07/31/2020 17:00 EDT Misc Exelixis Inc Second Quarter Earnings Conference Call in 2020
07/31/2020 Earnings Exelixis Inc Second Quarter Earnings in 2020 Release
05/20/2020 10:00 PDT Misc Exelixis Inc Annual General Meeting for 2019
05/05/2020 17:00 EDT Misc Exelixis Inc First Quarter Earnings Conference Call for 2020
05/05/2020 Earnings Exelixis Inc First Quarter Earnings Result for 2020
02/25/2020 17:00 EST Misc Exelixis Inc Fourth Quarter Earnings Conference Call for 2019
02/25/2020 Earnings Exelixis Inc Fourth Quarter Earnings in 2019 Release
02/25/2020 Misc Exelixis Inc Annual Report for 2019
10/30/2019 17:00 EDT Misc Exelixis Inc Third Quarter Earnings Conference Call for 2019
10/30/2019 Earnings Exelixis Inc Third Quarter Earnings in 2019 Release
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 979.20M
Total Expenses (TTM) 641.48M
Net Income (TTM) 293.85M

Balance Sheet View Statement

Total Assets (Quarterly) 1.956B
Total Liabilities (Quarterly) 207.95M
Shareholders Equity (Quarterly) 1.748B

Cash Flow Statement View Statement

Cash from Operations (TTM) 421.44M
Cash from Investing (TTM) -446.97M
Cash from Financing (TTM) 9.472M

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.exelixis.com
  • Investor Relations URL: http://www.exelixis.com/investors-media
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Jul. 31, 2020
  • Last Earnings Release: May. 05, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 23.94
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
FBT First Trust NYSE Arca Biotech ETF 3.61%
VLIIX Value Line Capital Appreciation Instl 3.48%
VLLIX Value Line Larger Companies Focus Instl 3.41%
APSRX Fiera Capital Small/Mid-Cap Growth Inv 2.27%
IMPLX ERShares US Large Cap Fund™ Inst 1.88%
RFG Invesco S&P MidCap 400® Pure Growth ETF 1.51%
VMFGX Vanguard S&P Mid-Cap 400 Growth Idx I 0.87%
IVOG Vanguard S&P Mid-Cap 400 Growth ETF 0.83%
IJK iShares S&P Mid-Cap 400 Growth ETF 0.83%
MDYG SPDR® S&P 400 Mid Cap Growth ETF 0.83%
ASQGX American Century Small Company R5 0.81%
IBB iShares Nasdaq Biotechnology ETF 0.76%

Comparables

Edit
BMY Bristol-Myers Squibb Co
PFE Pfizer Inc
CYCC Cyclacel Pharmaceuticals Inc
VBIV VBI Vaccines Inc
CODX Co-Diagnostics Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.